ReviewFunctional neurology
Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.
Review in Functional neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Utilisation of brain MRI for the diagnosis of dementia in low and middle-income countries: systematic review and meta-analysis.BMJ open · 2026Pooled it
- Fusion of Generative AI Techniques and Machine Learning Models to Generate and Investigate Biosignals for Glucose Sensors.ACS omega · 2025Article
- Article
- From Lesion to Decision: AI for ARIA Detection and Predictive Imaging in Alzheimer's Disease.Biomedicines · 2025Review
- Artificial Intelligence in Alzheimer's Disease Diagnosis and Prognosis Using PET-MRI: A Narrative Review of High-Impact Literature Post-Tauvid Approval.Journal of clinical medicine · 2025Review
- Advancing the Frontier: Neuroimaging Techniques in the Early Detection and Management of Neurodegenerative Diseases.Cureus · 2024Review
- Automated Synthesis of [Current radiopharmaceuticals · 2024Article
- Revolutionizing the Early Detection of Alzheimer's Disease through Non-Invasive Biomarkers: The Role of Artificial Intelligence and Deep Learning.Sensors (Basel, Switzerland) · 2023Review
- Association Between Acoustic Features and Brain Volumes: the Framingham Heart Study.Frontiers in dementia · 2023Article
- Early-onset Alzheimer's disease with depression as the first symptom: a case report with literature review.Frontiers in psychiatry · 2023Article
- Hippocampal atrophy is associated with hearing loss in cognitively normal adults.Frontiers in neuroscience · 2023Article
- Tensor-Based Multi-Modality Feature Selection and Regression for Alzheimer's Disease Diagnosis.Computer science & information technology · 2022Article
- Diagnosis of Alzheimer's Disease in Developed and Developing Countries: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy.Journal of Alzheimer's disease reports · 2021Article
- Quantitative Brain Positron Emission Tomography in Female 5XFAD Alzheimer Mice: Pathological Features and Sex-Specific Alterations.Frontiers in medicine · 2021Article
- The Clinical Spectrum of Young Onset Dementia Points to Its Stochastic Origins.Journal of Alzheimer's disease reports · 2021Article
- Detection of Active Caspase-3 in Mouse Models of Stroke and Alzheimer's Disease with a Novel Dual Positron Emission Tomography/Fluorescent Tracer [Contrast media & molecular imaging · 2019Article
- Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.Experimental gerontology · 2018Review
- Chemical exchange saturation transfer MRI shows low cerebral 2-deoxy-D-glucose uptake in a model of Alzheimer's Disease.Scientific reports · 2018Article
- Alzheimer-like brain metabolic and structural features in cholesterol-fed rabbit detected by magnetic resonance imaging.Lipids in health and disease · 2018Article
- From Matrices to Knowledge: Using Semantic Networks to Annotate the Connectome.Frontiers in neuroanatomy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroimaging, both with magnetic resonance imaging (MRI) and positron emission tomography (PET), has gained a pivotal role in the diagnosis of primary neurodegenerative diseases. These two techniques are used as biomarkers of both pathology and progression of Alzheimer's disease (AD) and to differentiate AD from other neurodegenerative diseases. MRI is able to identify structural changes including patterns of atrophy characterizing neurodegenerative diseases, and to distinguish these from other causes of cognitive impairment, e.g. infarcts, space-occupying lesions and hydrocephalus. PET is widely used to identify regional patterns of glucose utilization, since distinct patterns of distribution of cerebral glucose metabolism are related to different subtypes of neurodegenerative dementia. The use of PET in mild cognitive impairment, though controversial, is deemed helpful for predicting conversion to dementia and the dementia clinical subtype. Recently, new radiopharmaceuticals for the in vivo imaging of amyloid burden have been licensed and more tracers are being developed for the assessment of tauopathies and inflammatory processes, which may underlie the onset of the amyloid cascade. At present, the cerebral amyloid burden, imaged with PET, may help to exclude the presence of AD as well as forecast its possible onset. Finally PET imaging may be particularly useful in ongoing clinical trials for the development of dementia treatments. In the near future, the use of the above methods, in accordance with specific guidelines, along with the use of effective treatments will likely lead to more timely and successful treatment of neurodegenerative dementias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.